Risk of interstitial lung disease with the use of programmed cell death 1(PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis
Cancer Pathogenesis and Therapy（2023）
摘要
Image 1
更多查看译文
关键词
Programmed cell death 1 inhibitor,Programmed cell death ligand 1 inhibitor,Interstitial lung disease,Breast cancer,Immune-related adverse events
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要